Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29776965 | 0.80 | B3GNT2 (0.43) | B3GNT2ALDH1A1CYP3A4HPGDMEN1 | |
| SCHEMBL9257137 | 0.79 | KMT2A (0.51) | ALDH1A1CYP3A4HPGDMEN1KMT2A | |
| SCHEMBL16644078 | 0.79 | KMT2A (0.53) | B3GNT2ALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL1948407 | 0.79 | ALDH1A1 (0.56) | B3GNT2ALDH1A1CYP3A4HPGDMEN1 | |
| SCHEMBL5742355 | 0.76 | MAPT (0.41) | ALDH1A1CYP3A4HPGDMEN1KMT2A | |
| SCHEMBL8195993 | 0.75 | ALDH1A1 (0.43) | ALDH1A1CYP3A4HPGDMEN1KMT2A | |
| SCHEMBL5400116 | 0.75 | ALDH1A1 (0.42) | B3GNT2ALDH1A1CYP3A4HPGDMEN1 | |
| SCHEMBL2678032 | 0.74 | KMT2A (0.46) | ALDH1A1CYP3A4HPGDMEN1KMT2A | |
| SCHEMBL3985429 | 0.74 | MAPT (0.44) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL17467913 | 0.73 | ALDH1A1 (0.40) | ALDH1A1CYP3A4HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20070004761-A1 | Pyrazolo [3,4-d] pyrimidine derivatives and their use in the treatment of h.pylori infection | HETERO DRUGS LIMITED (IN) | 2007-01-04 | — | — | US | disclosed |
| EP-1585748-B1 | PYRAZOLO 3,4-d PYRIMIDINE DERIVATIVES AND THEIR USE I N THE TREATMENT OF H.PYLORI INFECTION | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| EP-1585748-A1 | PYRAZOLO 3,4-d PYRIMIDINE DERIVATIVES AND THEIR USE I N THE TREATMENT OF H.PYLORI INFECTION | AstraZeneca AB (SE) | 2005-10-19 | — | — | EP | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| WO-2004056831-A1 | PYRAZOLO [3,4-d] PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF H.PYLORI INFECTION | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | B3GNT2 514/4885ALDH1A1 903/4885CYP3A4 129/4885 |
| US-20070004761-A1 | Pyrazolo [3,4-d] pyrimidine derivatives and their use in the treatment of h.pylori infection | DPYD, TPMT, UMPS | B3GNT2 478/4885ALDH1A1 1865/4885CYP3A4 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.